Investigational Drug Information for Seletracetam
What is the development status for investigational drug Seletracetam?
Seletracetam is an investigational drug.
There have been 5 clinical trials for Seletracetam.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2006.
The most common disease conditions in clinical trials are Epilepsy, Seizures, and Epilepsies, Partial. The leading clinical trial sponsors are UCB Pharma and [disabled in preview].
Summary for Seletracetam
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 488 |
| WIPO Patent Applications | 234 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2006-02-01) |
| Vendors | 30 |
Recent Clinical Trials for Seletracetam
| Title | Sponsor | Phase |
|---|---|---|
| Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy | UCB Pharma | Phase 3 |
| A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures | UCB Pharma | Phase 2/Phase 3 |
| Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy. | UCB Pharma | Phase 3 |
Clinical Trial Summary for Seletracetam
Top disease conditions for Seletracetam
Top clinical trial sponsors for Seletracetam
US Patents for Seletracetam
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Seletracetam Development Update and Market Projection
Seletracetam is a discontinued UCB anticonvulsant candidate and a high-affinity synaptic vesicle protein 2A (SV2A) ligand. Public development activity did not progress to regulatory filing or commercial launch. Seletracetam has no FDA approval, no Orange Book listing, no marketed formulation, and no established generic or biosimilar pathway. Its commercial market projection is therefore effectively zero unless a sponsor revives the program and repeats late-stage clinical development.
What is seletracetam and how does it work?
Seletracetam, also identified as UCB 44212, is a small-molecule antiepileptic candidate developed by UCB. It targets SV2A, the same presynaptic vesicle protein targeted by levetiracetam and brivaracetam.
Preclinical studies characterized seletracetam as a potent SV2A ligand with anticonvulsant activity in several seizure models. The development rationale was to obtain stronger anticonvulsant activity than levetiracetam while preserving its broad mechanism and potentially favorable safety profile.
| Attribute | Seletracetam |
|---|---|
| Developer | UCB |
| Development code | UCB 44212 |
| Drug class | SV2A ligand |
| Intended indication | Epilepsy, particularly partial-onset seizures |
| Modality | Small molecule |
| Regulatory status | Not approved |
| FDA Orange Book status | No listing identified |
| Commercial status | Not marketed |
| Biosimilar relevance | None |
| Development status | Discontinued or inactive in publicly available development records |
Seletracetam differs from biologic epilepsy products because it is a conventional synthetic small molecule. Biosimilar competition is not relevant. If the candidate were revived, competition would arise from generic small-molecule antiepileptic drugs and branded SV2A agents.
What is the development status of seletracetam?
Seletracetam entered human clinical development but did not reach a successful Phase III registration program. Public records and UCB pipeline disclosures indicate that the company prioritized brivaracetam, another SV2A ligand, over seletracetam.
Brivaracetam ultimately became UCB’s commercial SV2A product and received FDA approval in 2016 under the brand name Briviact for adjunctive treatment of partial-onset seizures in patients aged two years and older. Seletracetam did not progress to an equivalent regulatory submission.
Development timeline
| Period | Development event |
|---|---|
| Early 2000s | UCB conducts preclinical work on seletracetam and related SV2A ligands |
| Mid-to-late 2000s | Seletracetam enters early clinical testing for epilepsy |
| Late 2000s to early 2010s | UCB advances brivaracetam as the lead next-generation SV2A program |
| 2010s | Public development activity for seletracetam declines and becomes inactive |
| 2016 | FDA approves brivaracetam, reducing the strategic need for a second UCB SV2A candidate |
| Through publicly available records | No FDA filing, approval, launch, or commercial partnership for seletracetam |
The absence of a New Drug Application, marketing authorization, commercial supply agreement, or active late-stage trial indicates that seletracetam is not an ongoing clinical asset in the conventional regulatory sense.
Why was seletracetam discontinued?
Public sources do not establish one definitive reason for discontinuation. The commercial explanation is clear: UCB had a more advanced SV2A candidate in brivaracetam, which provided a direct path to registration.
Several factors likely reduced the value of maintaining two closely related programs:
- Brivaracetam demonstrated sufficient clinical and regulatory potential.
- Seletracetam would have required additional dose-finding, efficacy, safety, and manufacturing work.
- A second SV2A product could have created internal portfolio overlap.
- The epilepsy market already contained inexpensive generic levetiracetam and multiple branded therapies.
- The commercial advantage of a second SV2A ligand would have depended on clinically meaningful differentiation in efficacy, tolerability, dosing, or drug interactions.
UCB’s public pipeline and annual-report disclosures subsequently emphasized brivaracetam rather than seletracetam. No public evidence shows that seletracetam was licensed to another company or transferred into an active development program.
What patents protect seletracetam?
Seletracetam was covered by UCB patent families directed to SV2A-binding pyrrolidone compounds, pharmaceutical compositions, and anticonvulsant uses. The relevant intellectual-property strategy likely included:
- Composition-of-matter claims covering the active molecule and related analogues.
- Pharmaceutical-composition claims covering tablets, capsules, solutions, and other dosage forms.
- Method-of-use claims for treating epilepsy and seizure disorders.
- Manufacturing and intermediate claims for producing the compound or its enantiomerically defined forms.
- Broader genus claims covering related SV2A ligands.
The commercial value of those rights has materially declined because the earliest patent families were filed during the 2000s and the program did not produce an approved product requiring regulatory exclusivity.
What is the patent expiration outlook?
A conventional U.S. utility patent generally has a term of 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and applicable extensions. Seletracetam’s core patent position appears to originate from early- to mid-2000s filings. On that basis, core U.S. patent terms would generally fall in the mid-2020s, with later formulation or method patents potentially extending beyond the basic compound claims.
There is no public Orange Book listing for seletracetam because the FDA has not approved the drug. As a result:
- No FDA-listed seletracetam patents define an approved-product exclusivity period.
- No Paragraph IV challenge is associated with an approved seletracetam product.
- No Hatch-Waxman litigation timetable exists.
- Any patent analysis must distinguish expired core claims from potentially surviving secondary claims.
A patent family can remain legally active in one country while being expired, abandoned, or unenforceable in another. Publicly available commercial records do not show a live, commercially relevant patent estate sufficient to support a current launch strategy.
Does seletracetam have FDA exclusivity or Orange Book protection?
No. Seletracetam has no FDA approval and therefore has no FDA new-drug exclusivity, orphan-drug exclusivity, pediatric exclusivity, or Orange Book-listed patents.
| FDA and Hatch-Waxman issue | Seletracetam status |
|---|---|
| FDA approval | None |
| NDA | No public approval record |
| Orange Book listing | None |
| New chemical entity exclusivity | Not awarded |
| Orphan-drug exclusivity | None identified |
| Pediatric exclusivity | None identified |
| Paragraph IV litigation | None associated with an approved product |
| Authorized generic | None |
| Generic launch | None |
The absence of regulatory exclusivity is distinct from patent expiry. Patents may have existed, but without an approved reference product they do not create a conventional abbreviated new drug application pathway.
What formulations are protected by seletracetam patents?
Public development information does not show a commercial seletracetam formulation. UCB’s patent strategy for small-molecule anticonvulsants would ordinarily address oral solid dosage forms, pharmaceutical compositions, and production processes.
The most commercially plausible dosage form would have been an immediate-release oral tablet or capsule. An oral liquid could have supported pediatric use, but no approved product label establishes such a formulation for seletracetam.
No public evidence establishes a durable formulation barrier comparable to a marketed extended-release product, transdermal system, implant, depot injection, or proprietary delivery device.
Which companies are challenging seletracetam patents?
No company is publicly identified as challenging seletracetam patents through a meaningful U.S. Paragraph IV case. The reason is structural: seletracetam was never approved and therefore did not generate a standard Orange Book reference-product litigation pathway.
Potential patent disputes could still arise in ordinary infringement or validity proceedings if a company attempted to commercialize the molecule. No material public litigation record indicates that such a dispute is active.
How does seletracetam compare with levetiracetam and brivaracetam?
Brivaracetam is the most relevant comparator because it is the successful UCB successor in the SV2A class. Levetiracetam is the broader market comparator because it established the class and became widely genericized.
| Factor | Seletracetam | Brivaracetam | Levetiracetam |
|---|---|---|---|
| Developer | UCB | UCB | UCB |
| SV2A mechanism | Yes | Yes | Yes |
| FDA approval | No | Yes, 2016 | Yes, 1999 |
| Commercial availability | None | Briviact and generic versions in some markets | Broad generic availability |
| Clinical development | Early and intermediate stages | Completed Phase III and regulatory review | Completed development |
| Patent-driven value | Historical | Reduced by generic and patent expiry pressure | Minimal in mature markets |
| Current commercial position | No revenue product | Established branded and generic competition | Large, low-cost generic base |
| Strategic role | Discontinued asset | UCB’s commercial SV2A franchise | Standard comparator and price anchor |
Brivaracetam’s approval substantially weakened the business case for reviving seletracetam. A revived program would need to show a clear clinical advantage over both brivaracetam and inexpensive levetiracetam.
What market opportunity would seletracetam have?
The addressable market would have been epilepsy, particularly focal-onset seizures. The commercial opportunity would have depended on differentiation rather than mechanism alone.
A new seletracetam launch would face:
- Generic levetiracetam at low prices.
- Brivaracetam as an approved high-affinity SV2A competitor.
- Established alternatives including lamotrigine, lacosamide, oxcarbazepine, topiramate, and valproate.
- Payer pressure against additional branded oral antiepileptic drugs.
- The need for long-term safety data in a chronic-use population.
- Limited commercial value from a molecule without a meaningful patent or exclusivity runway.
Revenue projection
| Scenario | Assumption | Estimated commercial outcome |
|---|---|---|
| Base case | Program remains inactive | $0 revenue |
| Revival without major differentiation | New sponsor funds development but product competes with generics and brivaracetam | Low commercial value; launch probability weak |
| Successful differentiated revival | New trials demonstrate superior efficacy, safety, adherence, or pharmacokinetics | Potential niche product, but revenue cannot be reliably modeled from public data |
| Partnership or licensing | UCB or a successor transfers rights | Possible transaction value, but no public deal establishes current valuation |
The base-case revenue forecast through 2030 is zero because there is no active regulatory program, no marketed product, and no public sponsor commitment. A meaningful revenue forecast would require a new clinical-development plan, a patent position with remaining term, a target label, pricing assumptions, and evidence of clinical differentiation.
What generic launch risks exist?
Generic competition is not an immediate launch risk because no seletracetam reference product exists. If the drug were revived and approved, generic risk would become material after any surviving composition, formulation, and regulatory exclusivity periods expired.
The most significant generic-entry risks would be:
- Early patent expiry for core composition claims.
- Weak or narrow formulation claims.
- Lack of pediatric, extended-release, or other differentiated exclusivity.
- Easy chemical synthesis and conventional oral manufacturing.
- A crowded therapeutic market with established generic substitutes.
Manufacturing would probably not be the main barrier. Seletracetam is a small molecule rather than a biologic, and the absence of a complex delivery system reduces process-development risk. The more significant barriers would be clinical development, regulatory approval, intellectual-property duration, and market access.
What licensing deals involve seletracetam?
No material public licensing or acquisition transaction has established a current commercial right to seletracetam. UCB appears to have retained control of its internal SV2A research portfolio while advancing brivaracetam as the lead product.
The absence of a public license is commercially important. It means there is no visible partner with an active development budget, regional commercialization plan, or manufacturing commitment.
How strong is the seletracetam patent estate?
The historical patent estate was technically relevant but commercially weak in its present form.
Strengths
- UCB originated the compound and related SV2A chemistry.
- Early composition patents may have provided meaningful protection during clinical development.
- The patent portfolio likely included broader chemical genera and therapeutic uses.
Weaknesses
- No approved product created Orange Book leverage.
- Core filing dates appear sufficiently old to limit remaining term.
- No public evidence shows an active formulation platform.
- The active market contains approved SV2A alternatives.
- A new sponsor would face substantial clinical and regulatory costs before realizing any exclusivity value.
Overall, seletracetam has low current patent-driven asset value. Its scientific mechanism remains understandable, but its commercial and legal position is materially inferior to an active, patent-protected development program.
Key Takeaways
- Seletracetam, or UCB 44212, is an inactive UCB SV2A anticonvulsant candidate.
- It did not reach FDA approval or commercial launch.
- UCB prioritized brivaracetam, which was approved in 2016.
- Seletracetam has no FDA Orange Book listing, FDA exclusivity, or established Paragraph IV litigation.
- Historical UCB patent families likely covered composition, formulations, uses, and manufacturing, but core protection is old and commercially weakened.
- No public licensing deal or active sponsor has revived the program.
- The base-case market projection is $0 through 2030.
- A revival would require new clinical trials and a clear advantage over generic levetiracetam and brivaracetam.
- Manufacturing is unlikely to be the principal barrier; regulatory cost, clinical differentiation, patent term, and reimbursement are more important.
FAQs
Is seletracetam the same drug as brivaracetam?
No. Both are SV2A ligands developed by UCB, but they are separate chemical entities. Brivaracetam completed development and received FDA approval; seletracetam did not.
Can a generic company launch seletracetam now?
There is no conventional ANDA pathway because seletracetam has never been approved as an FDA reference product. A company would need to pursue an independent regulatory strategy rather than rely on a standard generic application.
Is seletracetam still in clinical trials?
No active late-stage clinical program is publicly established. The development program is generally treated as inactive or discontinued.
Could seletracetam be repurposed for another neurological indication?
The mechanism could theoretically support evaluation in other seizure or neurological disorders, but no public regulatory program establishes a current repurposing strategy.
Does seletracetam have biosimilar competition?
No. Seletracetam is a synthetic small molecule, not a biologic. Any future competitors would be generics or new chemical entities, not biosimilars.
References
- U.S. Food and Drug Administration. (2016). FDA approves new drug to treat seizures associated with epilepsy. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- UCB. (Various years). Annual reports and research and development pipeline disclosures. UCB. https://www.ucb.com
- ClinicalTrials.gov. (n.d.). Clinical studies related to seletracetam and UCB 44212. U.S. National Library of Medicine. https://clinicaltrials.gov
- European Medicines Agency. (2016). Briviact: EPAR. https://www.ema.europa.eu
- National Center for Biotechnology Information. (n.d.). PubChem compound database: Seletracetam. https://pubchem.ncbi.nlm.nih.gov
- Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004). The synaptic vesicle protein SV2A is a binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences, 101(26), 9861-9866. https://doi.org/10.1073/pnas.0308208101
More… ↓
